Transaction · 0001838139-26-000026

Urist Marshall

Urist Marshall, EVP, reported an open-market or private sale at Royalty Pharma plc involving 4126.000000 shares for an estimated $238812.88. Reported holdings after the transaction were 4126.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SEVP
RPRXRoyalty Pharma plc
Filing timeSep 30
Trade dateSep 28, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded50%Shares sold ÷ (holdings after + shares sold). Estimated position before: 8,252 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$58.36
Pre-filing
1mo ago +4.3%1w ago +1.0%1d ago -0.3%
Returns since
7d30d90d180d1y

RPRX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RPRX since 2026-09-30Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001838139-26-000026
Class A Ordinary Shares
Transaction date
Sep 28, 2026
Filed Sep 30, 2026, 08:32 PM · 2d delay
Shares
4.12k sh
$57.88 per share
Estimated value
-$238k
Computed from shares × price
Holdings after
4.12k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Large Holdings Reduction 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP, Research & Investments

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026.

Original filing · 0001838139-26-000026
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RPRX